AKR1B10 and Digestive Tumors Development: a Review

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Dec 31

PMID 39737179

Authors

Yao Shen

Ailin Qiu

Xin Huang

Xiaosha Wen

Sundar Shehzadi

Yan He

Qian Hu

Jian Zhang

Dixian Luo

Shenghui Yang

Affiliations

Soon will be listed here.

Abstract

Aldo-keto reductase family 1 member B10 (AKR1B10) is a member of the AKR1B subfamily. It is mainly found in cytoplasm, and it is typically expressed in the stomach and intestines. Given that its expression is low or absent in other tissues, AKR1B10 is a potential diagnostic and therapeutic biomarker for various digestive system diseases. Here, we review recent research progress on AKR1B10 in digestive system tumors such as hepatocellular carcinoma, gastric carcinoma, colorectal carcinoma, pancreatic carcinoma, oral squamous cell carcinoma, laryngeal squamous cell carcinoma, cholangiocarcinoma, and nasopharyngeal carcinoma, over the last 5 years. We also discuss the current trends and future research directions for AKR1B10 in both oncological and non-oncological diseases to provide a scientific reference for further exploration of this gene.

References

Alannan M, Fayyad-Kazan H, Trezeguet V, Merched A . Targeting Lipid Metabolism in Liver Cancer. Biochemistry. 2020; 59(41):3951-3964. DOI: 10.1021/acs.biochem.0c00477. View

Tan Y, Wang Z, Xu M, Li B, Huang Z, Qin S . Oral squamous cell carcinomas: state of the field and emerging directions. Int J Oral Sci. 2023; 15(1):44. PMC: 10517027. DOI: 10.1038/s41368-023-00249-w. View

Connor J, Esbona K, Matkowskyj K . AKR1B10 expression by immunohistochemistry in surgical resections and fine needle aspiration cytology material in patients with cystic pancreatic lesions; potential for improved nonoperative diagnosis. Hum Pathol. 2017; 70:77-83. DOI: 10.1016/j.humpath.2017.10.006. View

Hara A, Endo S, Matsunaga T, Soda M, Yashiro K, El-Kabbani O . Long-chain fatty acids inhibit human members of the aldo-keto reductase 1C subfamily. J Biochem. 2017; 162(5):371-379. DOI: 10.1093/jb/mvx041. View

Kang M, Lee E, Yoon S, Jo J, Lee J, Kim H . AKR1B10 is associated with smoking and smoking-related non-small-cell lung cancer. J Int Med Res. 2011; 39(1):78-85. DOI: 10.1177/147323001103900110. View

Liu Y, Zhang J, Liu H, Guan G, Zhang T, Wang L . Compensatory upregulation of aldo-keto reductase 1B10 to protect hepatocytes against oxidative stress during hepatocarcinogenesis. Am J Cancer Res. 2020; 9(12):2730-2748. PMC: 6943354. View

Raggi C, Taddei M, Rae C, Braconi C, Marra F . Metabolic reprogramming in cholangiocarcinoma. J Hepatol. 2022; 77(3):849-864. DOI: 10.1016/j.jhep.2022.04.038. View

Xiong Y, Si Y, Feng Y, Zhuo S, Cui B, Zhang Z . Prognostic value of lipid metabolism-related genes in head and neck squamous cell carcinoma. Immun Inflamm Dis. 2020; 9(1):196-209. PMC: 7860527. DOI: 10.1002/iid3.379. View

Yao Y, Wang X, Zhou D, Li H, Qian H, Zhang J . Loss of AKR1B10 promotes colorectal cancer cells proliferation and migration via regulating FGF1-dependent pathway. Aging (Albany NY). 2020; 12(13):13059-13075. PMC: 7377871. DOI: 10.18632/aging.103393. View

10.

Penning T . The aldo-keto reductases (AKRs): Overview. Chem Biol Interact. 2014; 234:236-46. PMC: 4388799. DOI: 10.1016/j.cbi.2014.09.024. View

11.

Xie C, Ye X, Zeng L, Zeng X, Cao D . Serum AKR1B10 as an indicator of unfavorable survival of hepatocellular carcinoma. J Gastroenterol. 2023; 58(10):1030-1042. DOI: 10.1007/s00535-023-02011-9. View

12.

Yao H, Xu Y, Chen L, Guan T, Ma Y, He X . AKR1B10, a good prognostic indicator in gastric cancer. Eur J Surg Oncol. 2014; 40(3):318-24. DOI: 10.1016/j.ejso.2013.12.014. View

13.

Ru N, Xu X, Cao Y, Zhu J, Hu L, Wu S . The Impacts of Genetic and Environmental Factors on the Progression of Chronic Pancreatitis. Clin Gastroenterol Hepatol. 2021; 20(6):e1378-e1387. DOI: 10.1016/j.cgh.2021.08.033. View

14.

Feng G, Li X, Niu C, Liu M, Yan Q, Fan L . Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Gene. 2020; 742:144549. DOI: 10.1016/j.gene.2020.144549. View

15.

Barshir R, Fishilevich S, Iny-Stein T, Zelig O, Mazor Y, Guan-Golan Y . GeneCaRNA: A Comprehensive Gene-centric Database of Human Non-coding RNAs in the GeneCards Suite. J Mol Biol. 2021; 433(11):166913. DOI: 10.1016/j.jmb.2021.166913. View

16.

Morikawa Y, Kezuka C, Endo S, Ikari A, Soda M, Yamamura K . Acquisition of doxorubicin resistance facilitates migrating and invasive potentials of gastric cancer MKN45 cells through up-regulating aldo-keto reductase 1B10. Chem Biol Interact. 2015; 230:30-9. DOI: 10.1016/j.cbi.2015.02.005. View

17.

Letunic I, Khedkar S, Bork P . SMART: recent updates, new developments and status in 2020. Nucleic Acids Res. 2020; 49(D1):D458-D460. PMC: 7778883. DOI: 10.1093/nar/gkaa937. View

18.

Singh M, Kapoor A, Bhatnagar A . Oxidative and reductive metabolism of lipid-peroxidation derived carbonyls. Chem Biol Interact. 2015; 234:261-73. PMC: 4414726. DOI: 10.1016/j.cbi.2014.12.028. View

19.

Kong D, Wu Y, Tong B, Liang Y, Xu F, Chi X . CHES1 modulated tumorigenesis and senescence of pancreas cancer cells through repressing AKR1B10. Biochim Biophys Acta Mol Basis Dis. 2024; 1870(6):167214. DOI: 10.1016/j.bbadis.2024.167214. View

20.

Dai G, Wang L, Wen Y, Ren X, Zuo S . Identification of key genes for predicting colorectal cancer prognosis by integrated bioinformatics analysis. Oncol Lett. 2020; 19(1):388-398. PMC: 6924121. DOI: 10.3892/ol.2019.11068. View